Track market-moving stories before they get noisy

SummaryMetLife trades with a single-digit P/E multiple and about 10% earnings growth.With strength across segments and costs in control, the company continues to reward shareholders.The chart suggests significant upside leading into and through the Q3 earnings report due out next month. stecks05/iStock Editorial via Getty Images

Insurance inflation has cooled considerably from a few years ago, but that doesn't mean that insurance stocks are suffering. Case in point: MetLife (MET). The New York-based stalwart has returned 32% so far this

9.86K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Key Takeaways MetLife integrates pet insurance with ChatGPT, enabling conversational applications and personalized quotes.Rising veterinary costs drive demand, with 70% of pet owners delaying or skipping treatment due to expenses.MET's ChatGPT integration could boost policy sales and distribution efficiency, but claims costs remain key. MetLife, Inc. (MET - Free Report) is expanding its digital distribution strategy by integrating its pet insurance portal with ChatGPT. The insurer is the first major pet insurance provider to offer conversational applications and binding quotes through the platform. Customers can explore coverage, answer questions about their pets and obtain personalized quotes before completing purchases on MetLife’s website.

The launch comes amid rising veterinary expenses and low pet insurance penetration. MetLife’s data shows that one-third of employees worry about affording pet care, yet fewer than 10% have pet insurance. Meanwhile, 70% of pet owners have delayed or skipped veterinary treatment due to costs, with more than one-third reporting worsening pet conditions. These figures highlight growing demand for pet insurance coverage.

For MetLife, the strategic value lies in bringing insurance applications and quotes into a conversational platform. Simplifying the initial shopping process could help the insurer reach digitally engaged consumers and encourage more prospective customers to explore coverage. This provides another distribution channel without requiring a comparable expansion of traditional sales infrastructure.

The integration could support premium growth if increased customer engagement translates into additional policy sales. A streamlined application process may also improve distribution efficiency. However, higher policy volumes alone would not guarantee stronger profitability, as claims costs, pricing adequacy and customer retention will remain important determinants of underwriting performance.

MetLife has not disclosed financial targets or expected revenue contributions from the integration, leaving its near-term earnings impact uncertain. Its success will depend on whether the convenience of AI-assisted shopping translates into sustained policy sales. Nevertheless, the initiative expands its digital distribution capabilities and offers a potential long-term growth avenue.

How Are MetLife's Competitors Faring?A couple of MET's competitors in the pet insurance market are Chubb Limited (CB - Free Report) and The Progressive Corporation (PGR - Free Report) .

Chubb's Healthy Paws serves more than half a million pet owners, offering customizable insurance coverage, 24/7 virtual veterinary consultations and streamlined claims processing, with most claims processed within two days. These capabilities strengthen Chubb's competitive position by combining comprehensive pet insurance offerings with convenient digital services and efficient claims handling.

Progressive expanded its pet insurance business in January 2026 with a directly underwritten offering administered by Companion Protect, alongside its existing Pets Best arrangement. The new program offers customizable accident and illness coverage with optional wellness benefits, expanding PGR's product portfolio and strengthening its ability to capture growing demand for veterinary expense protection.

MetLife, Inc. (NYSE:MET – Get Free Report) announced a quarterly dividend on Tuesday, October 6th. Shareholders of record on Tuesday, November 3rd will be paid a dividend of $0.5925 per share by the financial services provider on Tuesday, December 8th. This represents a $2.37 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, November 3rd.

MetLife has increased its dividend by an average of 0.0%annually over the last three years and has raised its dividend annually for the last 12 consecutive years. MetLife has a payout ratio of 22.9% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect MetLife to earn $10.70 per share next year, which means the company should continue to be able to cover its $2.37 annual dividend with an expected future payout ratio of 22.1%.

MetLife Stock Performance Shares of MET stock opened at $97.22 on Wednesday. The company has a market capitalization of $62.56 billion, a P/E ratio of 18.63, a price-to-earnings-growth ratio of 0.92 and a beta of 0.78. MetLife has a 52 week low of $67.33 and a 52 week high of $100.93. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.20 and a current ratio of 0.20. The company’s 50 day moving average price is $96.53 and its two-hundred day moving average price is $87.17.

MetLife (NYSE:MET – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The financial services provider reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.13. MetLife had a net margin of 4.57% and a return on equity of 23.39%. The business had revenue of $13.52 billion for the quarter, compared to analyst estimates of $19.67 billion. During the same period last year, the business posted $2.02 earnings per share. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. On average, analysts expect that MetLife will post 9.85 earnings per share for the current fiscal year. Analysts Set New Price Targets A number of research firms recently issued reports on MET. Mizuho increased their price objective on MetLife from $95.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, July 9th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of MetLife in a research note on Friday, September 11th. Wells Fargo & Company boosted their price objective on shares of MetLife from $101.00 to $109.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 19th. TD Cowen increased their target price on shares of MetLife from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday. Finally, Morgan Stanley lifted their price target on shares of MetLife from $103.00 to $111.00 and gave the company an “overweight” rating in a research note on Monday, August 24th. Twelve investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $105.08.

View Our Latest Report on MET

About MetLife (Get Free Report)

MetLife, Inc is a global financial services company that provides insurance, employee benefits and retirement solutions. Its products and services include life insurance, dental and vision coverage, disability insurance, accident and health benefits, annuities, and savings and retirement products.

The company serves individuals, employers and institutions through group benefits, workplace solutions and individual insurance offerings. MetLife also provides investment and retirement services designed to help employers and employees prepare for long-term financial needs.

Founded in 1868, MetLife is headquartered in New York City and operates through businesses in the United States and international markets, including regions across Latin America, Asia and Europe.

See Also Five stocks we like better than MetLife Allient’s Data Center and Defense Momentum Is Raising the Stakes Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI Lamb Weston’s Turnaround Is Starting to Look Real These 3 Stocks Got the Most Love From Analysts in September

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

Argent Capital Management LLC purchased a new stake in MetLife, Inc. (NYSE:MET – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 121,303 shares of the financial services provider’s stock, valued at approximately $11,422,000.

Several other hedge funds have also modified their holdings of the stock. BlackRock Inc. purchased a new position in MetLife during the second quarter worth approximately $4,381,692,000. Pzena Investment Management LLC purchased a new stake in MetLife during the second quarter valued at about $941,792,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of MetLife by 5.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,026,518 shares of the financial services provider’s stock worth $509,904,000 after purchasing an additional 336,794 shares during the period. Bank of America Corp DE acquired a new position in MetLife during the second quarter valued at approximately $455,424,000. Finally, Legal & General Group Plc acquired a new stake in shares of MetLife in the second quarter worth $326,904,000. 94.99% of the stock is owned by institutional investors and hedge funds.

MetLife Stock Up 2.1% NYSE:MET traded up $2.00 during trading hours on Monday, reaching $96.43. The company’s stock had a trading volume of 1,059,373 shares, compared to its average volume of 3,631,547. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.20 and a quick ratio of 0.20. The company has a market cap of $62.05 billion, a price-to-earnings ratio of 18.46, a price-to-earnings-growth ratio of 0.90 and a beta of 0.78. MetLife, Inc. has a one year low of $67.33 and a one year high of $100.93. The business’s 50-day moving average is $96.51 and its 200-day moving average is $86.78.

MetLife (NYSE:MET – Get Free Report) last posted its earnings results on Wednesday, August 5th. The financial services provider reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.13. The company had revenue of $13.52 billion for the quarter, compared to analyst estimates of $19.67 billion. MetLife had a return on equity of 23.39% and a net margin of 4.57%.The business’s revenue was up 10.5% compared to the same quarter last year. During the same period last year, the company earned $2.02 earnings per share. Equities research analysts predict that MetLife, Inc. will post 9.83 EPS for the current year. MetLife announced that its board has authorized a stock buyback plan on Wednesday, August 5th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the financial services provider to reacquire up to 4.8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

MetLife Dividend Announcement The company also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 4th were issued a dividend of $0.5925 per share. This represents a $2.37 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date was Tuesday, August 4th. MetLife’s dividend payout ratio is 45.40%.

Analysts Set New Price Targets Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. lifted their price target on shares of MetLife from $106.00 to $108.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Keefe, Bruyette & Woods increased their price target on MetLife from $105.00 to $108.00 and gave the company an “outperform” rating in a report on Tuesday, August 11th. Atlantic Securities set a $103.00 price objective on MetLife in a report on Wednesday, July 15th. Weiss Ratings reiterated a “buy (b)” rating on shares of MetLife in a research note on Friday, September 11th. Finally, UBS Group lifted their price target on MetLife from $102.00 to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Twelve research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $104.69.

View Our Latest Analysis on MetLife

About MetLife (Free Report)

MetLife, Inc is a global financial services company that provides insurance, employee benefits and retirement solutions. Its products and services include life insurance, dental and vision coverage, disability insurance, accident and health benefits, annuities, and savings and retirement products.

The company serves individuals, employers and institutions through group benefits, workplace solutions and individual insurance offerings. MetLife also provides investment and retirement services designed to help employers and employees prepare for long-term financial needs.

Founded in 1868, MetLife is headquartered in New York City and operates through businesses in the United States and international markets, including regions across Latin America, Asia and Europe.

Read More Five stocks we like better than MetLife What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks Insiders Are Selling These 3 Stocks, Should You? Datadog’s Rally Has Insiders Selling—Can It Keep Climbing?

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

Life insurance companies like Prudential (PRU +0.40%) and MetLife (MET -0.32%) are generally very conservatively managed. That makes sense, since they take on financial obligations that can extend for decades, and they need to ensure they have the capital to meet them. This dynamic is an important part of why rising yields on 30-year Treasury bonds are largely a positive for insurance companies. Here's what you need to know.

What does a life insurance company do? Life insurance companies sell insurance that you don't actually want to use. In fact, you won't use it; your heirs, or whoever you designated as the beneficiary, will. That's a bit of an overstatement, since life insurance companies also sell retirement-oriented products like annuities. But the real point is the time frame that's involved. You generally buy life insurance or a variable annuity a long time before it will be needed.

Image source: Getty Images.

The life insurance company's job is to ensure it has the financial capacity to meet the obligations it has assumed. Those obligations can be decades away, so the premiums collected are generally invested conservatively. Usually, life insurance companies try to align their investments with the timing of their obligations. Often called matching liabilities, this generally means that bonds are bought and held to maturity.

If a bond is held to maturity, changes in price and yield between purchase and maturity aren't particularly important to a company's long-term outcomes. So rising rates just mean that a life insurance company can reinvest maturing bonds into higher-yielding ones, generating more interest income. From a big-picture view, rising yields are a win for life insurance companies like MetLife and Prudential.

Notably, nearly 73% of Prudential's investment portfolio is held in bonds. For reference, equities account for only about 1% of its portfolio, with the other assets focused on mortgage securities. MetLife's portfolio is a bit more aggressive, with bonds making up roughly 67% of the portfolio, stocks 0.02%, and mortgages and other institution-level assets (real estate and partnerships, for example) accounting for much of the rest. Still, the big story is the large bond exposure, which means that rising rates will boost the income these large life insurance companies produce.

Premium Feature

Moneyball Superscore

62/100

Today's Change

(

0.40

%) $

0.47

Current Price

$

118.40

There are other benefits, as well, since yields are used to calculate long-term liabilities. The math is complex, but higher rates reduce liabilities, freeing up capital for other purposes, such as selling more policies. And higher rates reduce the burden of guarantees on previously sold products. All in, rising yields are net positive for life insurance companies.

There are still some negatives to consider That said, rising rates are not just positive. There are some notable negatives to think about, too, even though the positives outweigh them.

For example, bond prices and bond yields move in opposite directions. Essentially, existing bond prices fall so the yields the bonds offer match the current market yield. If such bonds are held to maturity, this dynamic isn't that important, as noted above. However, it still reduces the value of a life insurer's portfolio over the short term until existing bonds mature and can be rolled over to new, higher-yielding bonds. An insurance company's book value can be pressured as yields rise.

Premium Feature

Moneyball Superscore

75/100

Today's Change

(

-0.32

%) $

-0.31

Current Price

$

97.04

Also, life insurance products sold when yields were lower may no longer be competitive with those currently available. That can lead some customers to ditch their old products and buy new ones. That churn can reduce the benefit that higher yields offer life insurance companies. The caveat here is that financial products tend to be fairly sticky, so this is likely to be an issue for a relatively small number of policies.

All in, higher yields are a win Life insurance is a complex industry where companies must align their investments with their financial obligations. That materially changes the story for the bonds companies like MetLife and Prudential own, as they are often held to maturity. This specific dynamic makes rising yields a win for life insurance companies, but there are other dynamics to consider, both positive and negative. All in, however, higher yields are likely to be a net positive, potentially for decades to come.

WHIPPANY, N.J.--(BUSINESS WIRE)--MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced the close of Galaxy 38 CLO, Ltd. (Galaxy 38), a $450 million target par new issue collateralized loan obligation (CLO). PineBridge Investments, which is part of MIM, serves as collateral manager for the transaction. BofA Securities, Inc. acted as arranger. Galaxy 38 marks the 45th CLO issuance by the Leveraged Finance team, building on t.

Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxisFewer than 1% of patients discontinued treatment due to treatment-related events at one yearNew findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment, /PRNewswire/ -- Johnson & Johnson NYSE:JNJ today announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib), with less frequent dosing and prophylactic strategies, can improve the treatment experience for patients with previously untreated advanced non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations. Early results show consistently low rates across key treatment-related events and treatment discontinuation.1

COPERNICUS was designed to reflect everyday clinical practice, enrolling a racially and ethnically diverse patient population across both academic and community sites. The data were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) (Abstract #M012.09).1

RYBREVANT FASPRO dual-targets EGFR and mesenchymal-epithelial transition (MET), two key drivers of tumor growth and treatment resistance, while also engaging the immune system.2,3,4,5 It is approved across multiple EGFR-mutated advanced NSCLC treatment settings and, for eligible patients, offers once-monthly dosing following initial weekly dosing.6

Advancing the treatment experience with RYBREVANT-based regimens

"RYBREVANT plus LAZCLUZE has already shown that patients with EGFR-mutated lung cancer can live longer, and these latest results mark an important evolution in the treatment approach," said Balazs Halmos, M.D., M.S., Director of Thoracic Oncology and Associate Director of Clinical Science, Montefiore Einstein Comprehensive Cancer Center. "With subcutaneous administration, less frequent dosing and prophylactic strategies, the regimen has been developed with the treatment experience in mind, helping patients start treatment and stay on it."

"Our work with RYBREVANT in EGFR-mutated lung cancer has continued to evolve with each new piece of evidence, from extending survival to advancing how treatment is delivered and managed," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. "COPERNICUS brings those learnings together in a study designed around the realities of clinical care. It reflects our commitment to continually innovate across the treatment journey so that scientific advances can make a meaningful difference for more patients."

Detailed study results

In this analysis, 214 U.S. patients received the recently approved RYBREVANT FASPRO plus LAZCLUZE regimen with prophylactic strategies to reduce the risk of blood clots with oral anticoagulation and skin-related side effects with an enhanced, easy-to-use skin care regimen evaluated in the COCOON study.1,7

At a median follow-up of 8.3 months, the majority of adverse events were Grade 1 or 2, with no new safety signals observed. Only eight percent of patients discontinued treatment due to adverse events. Rash was reported in 25 percent of patients, while administration-related reactions (ARRs) and venous thromboembolism (VTE) were each reported in three percent. No patients discontinued due to ARRs, and one percent discontinued due to rash and VTE.1

These findings represent lower numerical rates than observed with intravenous RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE in the Phase 3 MARIPOSA study, where rash, ARRs and VTE during the first four months of treatment were reported in 55 percent, 55 percent and 23 percent of patients, respectively. MARIPOSA also demonstrated that patients with advanced EGFR-mutated advanced NSCLC treated with the first-line regimen lived longer than those treated with osimertinib, with a statistically significant overall survival benefit (hazard ratio [HR], 0.75; P=0.005).8

COPERNICUS is one of the largest global studies conducted in patients with EGFR-mutated NSCLC, with a target enrollment of 300 previously untreated patients. Of the population reported here, median age was 67 years, 22 percent were age 75 or older, 27 percent were Asian, 10 percent were African American and 10 percent were Hispanic/Latino.1

This study reflects Johnson & Johnson's continued focus on improving the treatment experience for people with cancer, including how treatments are delivered and managed in everyday care.

About the COPERNICUS study

COPERNICUS (NCT06667076) is a Phase 2b, single-arm study evaluating RYBREVANT FASPRO plus LAZCLUZE with prophylactic strategies in patients with EGFR-mutated advanced non-small cell lung cancer. Cohort 1 evaluates the regimen in the first-line setting, incorporating once-every-four-weeks dosing, venous thromboembolism (VTE) and enhanced dermatologic prophylaxis.

The study uses a pragmatic design to more closely reflect real-world clinical practice, with participation from academic and community sites and reduced visit frequency. The primary endpoint is investigator-assessed progression-free survival per RECIST v1.1. Secondary endpoints include safety and tolerability measures, including VTE and dermatologic adverse events and administration-related reactions, as well as overall survival and overall response rate.9

About non-small cell lung cancer

Worldwide, lung cancer is one of the most common cancers, with non-small cell lung cancer (NSCLC) making up 80 to 85 percent of all lung cancer cases.10,11 The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.12 Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.13 EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.10,11,14,15,16,17 EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.18 The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent.19,20 EGFR exon 20 insertion mutations are the third-most prevalent activating EGFR mutation.21 Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.22

About RYBREVANT FASPRO and RYBREVANT

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) received U.S. FDA approval in December 2025 and is approved in multiple markets worldwide for the treatment of adults with EGFR-mutated non-small cell lung cancer (NSCLC), including those with exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 insertion mutations. It is the only subcutaneous therapy approved for these EGFR-mutated NSCLC populations and may be used as monotherapy or in combination with LAZCLUZE (lazertinib) or chemotherapy, depending on the specific mutation and treatment setting. For eligible patients, RYBREVANT FASPRO offers a once-monthly dosing option following initial weekly dosing. RYBREVANT FASPRO is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology.

RYBREVANT FASPRO is approved in the U.S. for the same indications as intravenous RYBREVANT (amivantamab-vmjw) across multiple markets. RYBREVANT is a first-in-class, fully human bispecific antibody targeting EGFR and MET, designed to inhibit tumor growth while engaging the immune system.

The effectiveness of RYBREVANT FASPRO is supported by the established clinical profile of RYBREVANT, including data from multiple Phase 3 studies such as MARIPOSA, which demonstrated improvements in progression-free and overall survival when used in combination with LAZCLUZE® in first-line advanced EGFR-mutated NSCLC.

The National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®)‡ 23 include amivantamab-vmjw (RYBREVANT) across its FDA-approved treatment settings, including as a Category 1 preferred option in combination with lazertinib (LAZCLUZE) for first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations. Subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO) may be substituted for IV amivantamab-vmjw (RYBREVANT) where appropriate. See the latest NCCN Guidelines® for NSCLC for complete information.§ ||

The NCCN Guidelines for Central Nervous System Cancers also include amivantamab (RYBREVANT)-based regimens, including in combination with lazertinib (LAZCLUZE), as the only NCCN-preferred combination options for patients with EGFR-mutated NSCLC and brain metastases.§ ||

Beyond NSCLC, RYBREVANT-based therapies are being investigated across other solid tumors, including head and neck and colorectal cancers.

The legal manufacturer for RYBREVANT FASPRO and RYBREVANT is Janssen Biotech, Inc. For more information, visit www.rybrevanthcp.com.

INDICATIONS

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) and RYBREVANT (amivantamab-vmjw) are indicated:

in combination with LAZCLUZE (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA approved test, whose disease has progressed on or after platinum-based chemotherapy.IMPORTANT SAFETY INFORMATION FOR RYBREVANT FASPRO AND RYBREVANT 6,24

CONTRAINDICATIONS

RYBREVANT FASPRO is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity and Administration-Related Reactions with RYBREVANT FASPRO

RYBREVANT FASPRO can cause hypersensitivity and administration-related reactions (ARR); signs and symptoms of ARR include dyspnea, flushing, fever, chills, chest discomfort, hypotension, and vomiting. The median time to ARR onset is approximately 2 hours.

RYBREVANT FASPRO with LAZCLUZE

In PALOMA-3 (n=206), all Grade ARR occurred in 13% of patients, including 0.5% Grade 3. Of the patients who experienced ARR, 89% occurred with the initial dose (Week 1, Day 1).

Premedicate with antihistamines, antipyretics, and glucocorticoids and administer RYBREVANT FASPRO as recommended. Monitor patients for any signs and symptoms of administration-related reactions during injection in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt RYBREVANT FASPRO injection if ARR is suspected. Resume treatment upon resolution of symptoms or permanently discontinue RYBREVANT FASPRO based on severity.

Infusion-Related Reactions with RYBREVANT

RYBREVANT can cause infusion-related reactions (IRR) including anaphylaxis; signs and symptoms of IRR include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting. The median time to IRR onset is approximately 1 hour.

RYBREVANT with LAZCLUZE

In MARIPOSA (n=421), IRRs occurred in 63% of patients, including Grade 3 in 5% and Grade 4 in 1% of patients. IRR-related infusion modifications occurred in 54%, dose reduction in 0.7%, and permanent discontinuation of RYBREVANT in 4.5% of patients.

RYBREVANT with Carboplatin and Pemetrexed

Based on the pooled safety population (n=281), IRRs occurred in 50% of patients including Grade 3 (3.2%) adverse reactions. IRR-related infusion modifications occurred in 46%, and permanent discontinuation of RYBREVANT in 2.8% of patients.

RYBREVANT as a Single Agent

In CHRYSALIS (n=302), IRRs occurred in 66% of patients. IRRs occurred in 65% of patients on Week 1 Day 1, 3.4% on Day 2 infusion, 0.4% with Week 2 infusion, and were cumulatively 1.1% with subsequent infusions. 97% were Grade 1-2, 2.2% were Grade 3, and 0.4% were Grade 4. The median time to onset was 1 hour (range: 0.1 to 18 hours) after start of infusion. IRR-related infusion modifications occurred in 62%, and permanent discontinuation of RYBREVANT in 1.3% of patients.

Premedicate with antihistamines, antipyretics, and glucocorticoids and infuse RYBREVANT as recommended. Administer RYBREVANT via a peripheral line on Week 1 and Week 2 to reduce the risk of IRRs. Monitor patients for signs and symptoms of IRRs in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt infusion if IRR is suspected. Reduce the infusion rate or permanently discontinue RYBREVANT based on severity. If an anaphylactic reaction occurs, permanently discontinue RYBREVANT.

Interstitial Lung Disease/Pneumonitis

RYBREVANT FASPRO and RYBREVANT can cause severe and fatal interstitial lung disease (ILD)/pneumonitis.

RYBREVANT FASPRO with LAZCLUZE

In PALOMA-3, ILD/pneumonitis occurred in 6% of patients, including Grade 3 in 1%, Grade 4 in 1.5%, and fatal cases in 1.9% of patients. 5% of patients permanently discontinued RYBREVANT FASPRO and LAZCLUZE due to ILD/pneumonitis.

RYBREVANT with LAZCLUZE

In MARIPOSA, ILD/pneumonitis occurred in 3.1% of patients, including Grade 3 in 1.0% and Grade 4 in 0.2% of patients. There was one fatal case of ILD/pneumonitis and 2.9% of patients permanently discontinued RYBREVANT and LAZCLUZE due to ILD/pneumonitis.

RYBREVANT with Carboplatin and Pemetrexed

Based on the pooled safety population, ILD/pneumonitis occurred in 2.1% of patients with 1.8% of patients experiencing Grade 3 ILD/pneumonitis. 2.1% discontinued RYBREVANT due to ILD/pneumonitis.

RYBREVANT as a Single Agent

In CHRYSALIS, ILD/pneumonitis occurred in 3.3% of patients, with 0.7% of patients experiencing Grade 3 ILD/pneumonitis. Three patients (1%) permanently discontinued RYBREVANT due to ILD/pneumonitis.

Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold RYBREVANT FASPRO or RYBREVANT and LAZCLUZE (when applicable) in patients with suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is confirmed.

Venous Thromboembolic (VTE) Events with Concomitant Use with LAZCLUZE

RYBREVANT FASPRO and RYBREVANT in combination with LAZCLUZE can cause serious and fatal venous thromboembolic (VTE) events, including deep vein thrombosis and pulmonary embolism. Without prophylactic anticoagulation, the majority of these events occurred during the first four months of treatment.

RYBREVANT FASPRO with LAZCLUZE

In PALOMA-3 (n=206), all Grade VTE occurred in 11% of patients and 1.5% were Grade 3. 80% (n=164) of patients received prophylactic anticoagulation at study entry, with an all Grade VTE incidence of 7%. In patients who did not receive prophylactic anticoagulation (n=42), all Grade VTE occurred in 17% of patients. In total, 0.5% of patients had VTE leading to dose reductions of RYBREVANT FASPRO and no patients required permanent discontinuation. The median time to onset of VTEs was 95 days (range: 17 to 390).

RYBREVANT with LAZCLUZE

In MARIPOSA (n=421), VTEs occurred in 36% of patients including Grade 3 in 10% and Grade 4 in 0.5% of patients. On-study VTEs occurred in 1.2% of patients (n=5) while receiving anticoagulation therapy. There were two fatal cases of VTE (0.5%), 9% of patients had VTE leading to dose interruptions of RYBREVANT, and 7% of patients had VTE leading to dose interruptions of LAZCLUZE; 1% of patients had VTE leading to dose reductions of RYBREVANT, and 0.5% of patients had VTE leading to dose reductions of LAZCLUZE; 3.1% of patients had VTE leading to permanent discontinuation of RYBREVANT, and 1.9% of patients had VTE leading to permanent discontinuation of LAZCLUZE. The median time to onset of VTEs was 84 days (range: 6 to 777).

Administer prophylactic anticoagulation for the first four months of treatment. The use of Vitamin K antagonists is not recommended.

Monitor for signs and symptoms of VTE events and treat as medically appropriate. Withhold RYBREVANT FASPRO or RYBREVANT and LAZCLUZE based on severity. Once anticoagulant treatment has been initiated, resume RYBREVANT FASPRO or RYBREVANT and LAZCLUZE at the same dose level at the discretion of the healthcare provider. In the event of VTE recurrence despite therapeutic anticoagulation, permanently discontinue RYBREVANT FASPRO or RYBREVANT. Treatment can continue with LAZCLUZE at the same dose level at the discretion of the healthcare provider. Refer to the LAZCLUZE Prescribing Information for recommended LAZCLUZE dosage modification.

Dermatologic Adverse Reactions

RYBREVANT FASPRO and RYBREVANT can cause severe rash including toxic epidermal necrolysis (TEN), dermatitis acneiform, pruritus and dry skin.

RYBREVANT FASPRO with LAZCLUZE

In PALOMA-3, rash occurred in 80% of patients, including Grade 3 in 17% and Grade 4 in 0.5% of patients. Rash leading to dose reduction occurred in 11% of patients, and RYBREVANT FASPRO was permanently discontinued due to rash in 1.5% of patients.

RYBREVANT with LAZCLUZE

In MARIPOSA, rash occurred in 86% of patients, including Grade 3 in 26% of patients. The median time to onset of rash was 14 days (range: 1 to 556 days). Rash leading to dose interruptions occurred in 37% of patients for RYBREVANT and 30% for LAZCLUZE, rash leading to dose reductions occurred in 23% of patients for RYBREVANT and 19% for LAZCLUZE, and rash leading to permanent discontinuation occurred in 5% of patients for RYBREVANT and 1.7% for LAZCLUZE.

RYBREVANT with Carboplatin and Pemetrexed

Based on the pooled safety population, rash occurred in 82% of patients, including Grade 3 (15%) adverse reactions. Rash leading to dose reductions occurred in 14% of patients, and 2.5% permanently discontinued RYBREVANT and 3.1% discontinued pemetrexed.

RYBREVANT as a Single Agent

In CHRYSALIS, rash occurred in 74% of patients, including Grade 3 in 3.3% of patients. The median time to onset of rash was 14 days (range: 1 to 276 days). Rash leading to dose reduction occurred in 5% and permanent discontinuation due to rash occurred in 0.7% of patients. Toxic epidermal necrolysis occurred in one patient (0.3%).

When initiating treatment with RYBREVANT FASPRO or RYBREVANT and LAZCLUZE, prophylactic and concomitant medications are recommended to reduce the risk and severity of dermatologic adverse reactions. Instruct patients to limit sun exposure during and for 2 months after treatment. Advise patients to wear protective clothing and use broad spectrum UVA/UVB sunscreen.

If skin reactions develop, administer supportive care including topical corticosteroids and topical and/or oral antibiotics. For Grade 3 reactions, add oral steroids and consider dermatologic consultation. Promptly refer patients presenting with severe rash, atypical appearance or distribution, or lack of improvement within 2 weeks to a dermatologist. For patients receiving RYBREVANT FASPRO or RYBREVANT in combination with LAZCLUZE, withhold, reduce the dose, or permanently discontinue both drugs based on severity. For patients receiving RYBREVANT FASPRO or RYBREVANT as a single agent or in combination with carboplatin and pemetrexed, withhold, dose reduce or permanently discontinue RYBREVANT FASPRO or RYBREVANT based on severity

Hepatotoxicity

LAZCLUZE in combination with amivantamab can cause severe hepatotoxicity (including increased ALT and AST).

RYBREVANT with LAZCLUZE

In MARIPOSA, based on adverse reaction data, hepatotoxicity occurred in 49% of patients treated with LAZCLUZE, including Grade 3 in 9.3% of patients and Grade 4 in 0.5%. LAZCLUZE was interrupted for an adverse reaction of hepatotoxicity in 8% of patients, the dose was reduced in 1.4% and permanently discontinued in 0.2%.

Perform liver function tests (including ALT, AST, and total bilirubin) before initiation of LAZCLUZE and during treatment, as clinically indicated. Withhold, reduce the dose, or permanently discontinue LAZCLUZE and amivantamab based on severity.

Ocular Toxicity

RYBREVANT FASPRO and RYBREVANT can cause ocular toxicity including keratitis, blepharitis, dry eye symptoms, conjunctival redness, blurred vision, visual impairment, ocular itching, eye pruritus and uveitis.

RYBREVANT FASPRO with LAZCLUZE

In PALOMA-3, all Grade ocular toxicity occurred in 13% of patients, including 0.5% Grade 3.

RYBREVANT with LAZCLUZE

In MARIPOSA, ocular toxicity occurred in 16%, including Grade 3 or 4 ocular toxicity in 0.7% of patients.

RYBREVANT with Carboplatin and Pemetrexed

Based on the pooled safety population, ocular toxicity occurred in 16% of patients. All events were Grade 1 or 2.

RYBREVANT as a Single Agent

In CHRYSALIS, keratitis occurred in 0.7% and uveitis occurred in 0.3% of patients. All events were Grade 1-2.

Promptly refer patients presenting with new or worsening eye symptoms to an ophthalmologist. Withhold, dose reduce or permanently discontinue RYBREVANT FASPRO or RYBREVANT and continue LAZCLUZE based on severity.

Embryo-Fetal Toxicity

Based on animal models, RYBREVANT FASPRO, RYBREVANT and LAZCLUZE can cause fetal harm when administered to a pregnant woman. Verify pregnancy status of females of reproductive potential prior to initiating RYBREVANT FASPRO and RYBREVANT. Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise patients of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of RYBREVANT FASPRO or RYBREVANT, and for 3 weeks after the last dose of LAZCLUZE.

ADVERSE REACTIONS

RYBREVANT FASPRO with LAZCLUZE

In PALOMA-3 (n=206), the most common adverse reactions (≥20%) were rash (80%), nail toxicity (58%), musculoskeletal pain (50%), fatigue (37%), stomatitis (36%), edema (34%), nausea (30%), diarrhea (22%), vomiting (22%), constipation (22%), decreased appetite (22%), and headache (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased lymphocyte count (6%), decreased sodium (5%), decreased potassium (5%), decreased albumin (4.9%), increased alanine aminotransferase (3.4%), decreased platelet count (2.4%), increased aspartate aminotransferase (2%), increased gamma-glutamyl transferase (2%), and decreased hemoglobin (2%).

Serious adverse reactions occurred in 33% of patients, with those occurring in ≥2% of patients including ILD/pneumonitis (6%); and pneumonia, VTE and fatigue (2.4% each). Death due to adverse reactions occurred in 5% of patients treated with RYBREVANT FASPRO, including ILD/pneumonitis (1.9%), pneumonia (1.5%), and respiratory failure and sudden death (1% each).

RYBREVANT with LAZCLUZE

In MARIPOSA (n=421), the most common adverse reactions (ARs) (≥20%) were rash (86%), nail toxicity (71%), infusion-related reactions (IRRs) (RYBREVANT) (63%), musculoskeletal pain (47%), stomatitis (43%), edema (43%), VTE (36%), paresthesia (35%), fatigue (32%), diarrhea (31%), constipation (29%), COVID-19 (26%), hemorrhage (25%), dry skin (25%), decreased appetite (24%), pruritus (24%), and nausea (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).

Serious ARs occurred in 49% of patients, with those occurring in ≥2% of patients including VTE (11%), pneumonia (4%), ILD/pneumonitis and rash (2.9% each), COVID-19 (2.4%), and pleural effusion and IRRs (RYBREVANT) (2.1% each). Fatal ARs occurred in 7% of patients due to death not otherwise specified (1.2%); sepsis and respiratory failure (1% each); pneumonia, myocardial infarction, and sudden death (0.7% each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).

RYBREVANT with Carboplatin and Pemetrexed

In MARIPOSA-2 (n=130), the most common ARs (≥20%) were rash (72%), IRRs (59%), fatigue (51%), nail toxicity (45%), nausea (45%), constipation (39%), edema (36%), stomatitis (35%), decreased appetite (31%), musculoskeletal pain (30%), vomiting (25%), and COVID-19 (21%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased neutrophils (49%), decreased white blood cells (42%), decreased lymphocytes (28%), decreased platelets (17%), decreased hemoglobin (12%), decreased potassium (11%), decreased sodium (11%), increased alanine aminotransferase (3.9%), decreased albumin (3.8%), and increased gamma-glutamyl transferase (3.1%).

In MARIPOSA-2, serious ARs occurred in 32% of patients, with those occurring in >2% of patients including dyspnea (3.1%), thrombocytopenia (3.1%), sepsis (2.3%), and PE (2.3%). Fatal ARs occurred in 2.3% of patients; these included respiratory failure, sepsis, and ventricular fibrillation (0.8% each).

In PAPILLON (n=151), the most common ARs (≥20%) were rash (90%), nail toxicity (62%), stomatitis (43%), IRRs (42%), fatigue (42%), edema (40%), constipation (40%), decreased appetite (36%), nausea (36%), COVID-19 (24%), diarrhea (21%), and vomiting (21%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased albumin (7%), increased alanine aminotransferase (4%), increased gamma-glutamyl transferase (4%), decreased sodium (7%), decreased potassium (11%), decreased magnesium (2%), and decreases in white blood cells (17%), hemoglobin (11%), neutrophils (36%), platelets (10%), and lymphocytes (11%).

In PAPILLON, serious ARs occurred in 37% of patients, with those occurring in ≥2% of patients including rash, pneumonia, ILD, PE, vomiting, and COVID-19. Fatal adverse reactions occurred in 7 patients (4.6%) due to pneumonia, cerebrovascular accident, cardio-respiratory arrest, COVID-19, sepsis, and death not otherwise specified.

RYBREVANT as a Single Agent

In CHRYSALIS (n=129), the most common ARs (≥20%) were rash (84%), IRR (64%), paronychia (50%), musculoskeletal pain (47%), dyspnea (37%), nausea (36%), fatigue (33%), edema (27%), stomatitis (26%), cough (25%), constipation (23%), and vomiting (22%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased lymphocytes (8%), decreased albumin (8%), decreased phosphate (8%), decreased potassium (6%), increased alkaline phosphatase (4.8%), increased glucose (4%), increased gamma-glutamyl transferase (4%), and decreased sodium (4%).

Serious ARs occurred in 30% of patients, with those occurring in ≥2% of patients including PE, pneumonitis/ILD, dyspnea, musculoskeletal pain, pneumonia, and muscular weakness. Fatal adverse reactions occurred in 2 patients (1.5%) due to pneumonia and 1 patient (0.8%) due to sudden death.

LAZCLUZE DRUG INTERACTIONS

Avoid concomitant use of LAZCLUZE with strong and moderate CYP3A4 inducers. Consider an alternate concomitant medication with no potential to induce CYP3A4.

Monitor for adverse reactions associated with a CYP3A4 or BCRP substrate where minimal concentration changes may lead to serious adverse reactions, as recommended in the approved product labeling for the CYP3A4 or BCRP substrate.

Please see full Prescribing Information for RYBREVANT FASPRO, RYBREVANT and LAZCLUZE.

cp-491009v2

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of RYBREVANT®-based regimens. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

* Balazs Halmos, M.D., M.S., has served as a consultant to Johnson & Johnson; he has not been paid for any media work.

† RECIST (version 1.1) refers to Response Evaluation Criteria in Solid Tumors, which is a standard way to measure how well
solid tumors respond to treatment and is based on whether tumors shrink, stay the same or get bigger.

‡ The NCCN content does not constitute medical advice and should not be used in place of seeking professional medical advice, diagnosis or treatment by licensed practitioners. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

§ See the NCCN Guidelines for detailed recommendations, including other treatment options.

|| The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories.

Source: Johnson & Johnson

1 Halmos B, et al. Subcutaneous amivantamab + lazertinib with supportive care in EGFR-mutant NSCLC: Longer follow-up from the pragmatic COPERNICUS study. Presented at: IASLC 2026 World Conference on Lung Cancer; 2026; Seoul.

2 Moores SL, Chiu ML, Bushey BS, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. Cancer Res. 2016;76(13):3942-3953. doi:10.1158/0008-5472.CAN-15-2833

3 Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Mol Cancer Ther. 2020;19(10):2044-2056. doi:10.1158/1535-7163.MCT-20-0071

4 Yun J, Lee SH, Kim SY, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020;10(8):1194-1209. doi:10.1158/2159-8290.CD-20-0116

5 Soo R, et al. Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer. Lung Cancer. Published online May 22, 2026. doi:10.1016/S0169-5002(26)00466-6.

6 RYBREVANT FASPRO [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

7 Cho BC, Li W, Spira AI, et al. Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: the COCOON global randomized controlled trial. J Thorac Oncol. 2025;20(10):1517-1530. doi:10.1016/j.jtho.2025.07.117.

8 Yang JCH, Lu S, Hayashi H, et al. Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC. N Engl J Med. 2025;393(17):1681-1693. doi:10.1056/NEJMoa2503001.

9 ClinicalTrials.gov. A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (COPERNICUS). Accessed September 2026. https://clinicaltrials.gov/study/NCT06667076

10 The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed September 2026.

11 American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed September 2026.

12 Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.

13 Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

14 Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol. 2019;37(2):97-104.

15 Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

16 Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.

17 Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.

18 American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed September 2026.

19 Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.

20 Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65.

21 Arcila, M. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013 Feb; 12(2):220-9.

22 Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

23 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.7.2026 © National Comprehensive Cancer Network, Inc. All rights reserved. Accessed September 2026. To view the most recent and complete version of the guideline, go online to NCCN.org.

24 RYBREVANT [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-lazcluze-lazertinib-with-prophylactic-strategies-shows-low-rates-of-treatment-related-events-at-wclc-2026-302878165.html

SOURCE Johnson & Johnson

MetLife (NYSE:MET – Get Free Report) and Global Indemnity Group (NASDAQ:GBLI – Get Free Report) are both finance companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Valuation and Earnings This table compares MetLife and Global Indemnity Group”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetLife $77.08 billion 0.81 $3.38 billion $5.22 18.60 Global Indemnity Group $450.10 million 0.97 $25.33 million $2.35 12.66 MetLife has higher revenue and earnings than Global Indemnity Group. Global Indemnity Group is trading at a lower price-to-earnings ratio than MetLife, indicating that it is currently the more affordable of the two stocks. Volatility and Risk MetLife has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Global Indemnity Group has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.

Dividends MetLife pays an annual dividend of $2.37 per share and has a dividend yield of 2.4%. Global Indemnity Group pays an annual dividend of $1.40 per share and has a dividend yield of 4.7%. MetLife pays out 45.4% of its earnings in the form of a dividend. Global Indemnity Group pays out 59.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. MetLife has increased its dividend for 12 consecutive years and Global Indemnity Group has increased its dividend for 1 consecutive years.

Insider and Institutional Ownership 95.0% of MetLife shares are held by institutional investors. Comparatively, 37.4% of Global Indemnity Group shares are held by institutional investors. 0.4% of MetLife shares are held by company insiders. Comparatively, 47.1% of Global Indemnity Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability This table compares MetLife and Global Indemnity Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets MetLife 4.57% 23.39% 0.89% Global Indemnity Group 7.50% 5.56% 2.28% Analyst Ratings This is a breakdown of current recommendations for MetLife and Global Indemnity Group, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetLife 0 1 11 1 3.00 Global Indemnity Group 0 1 0 0 2.00 MetLife currently has a consensus target price of $102.21, indicating a potential upside of 5.30%. Given MetLife’s stronger consensus rating and higher probable upside, research analysts clearly believe MetLife is more favorable than Global Indemnity Group.

Summary MetLife beats Global Indemnity Group on 13 of the 18 factors compared between the two stocks.

About MetLife (Get Free Report)

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was incorporated in 1999 and is based in New York, New York.

(Get Free Report)

Global Indemnity Group, LLC, through its subsidiaries, provides specialty property and casualty insurance, and reinsurance products worldwide. It operates in two segments, Penn-America and Non-Core Operations. The company distributes property and general liability products for small commercial businesses through a network of wholesale general agents; and property and general liability niche products through program administrators with specific binding authority. It also provides third-party treaty reinsurance for casualty insurance and reinsurance companies through brokers/intermediaries. In addition, the company offers property and general liability products distributed using company administered systems, and includes collectibles, digital direct-to-consumer insurance coverage for owners of collections; and VacantExpress, insurance coverage for owners of properties under construction, renovation, vacant, or rented, distributed through wholesale general agents and retail agents. Global Indemnity Group, LLC was founded in 2003 and is headquartered in Bala Cynwyd, Pennsylvania.

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

California State Teachers Retirement System boosted its stake in shares of MetLife, Inc. (NYSE:MET – Free Report) by 8,029.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,771,290 shares of the financial services provider’s stock after buying an additional 72,863,779 shares during the period. California State Teachers Retirement System owned approximately 11.47% of MetLife worth $6,241,789,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in MET. Mowery & Schoenfeld Wealth Management LLC purchased a new position in shares of MetLife in the 2nd quarter worth about $26,000. Burk Holdings LLC bought a new position in shares of MetLife in the second quarter worth approximately $27,000. Highland Investment Advisors LLC purchased a new stake in shares of MetLife during the second quarter valued at approximately $30,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of MetLife during the fourth quarter valued at approximately $30,000. Finally, Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new position in MetLife in the 4th quarter worth approximately $31,000. 94.99% of the stock is owned by institutional investors.

MetLife Trading Up 0.3% MetLife stock opened at $95.82 on Thursday. MetLife, Inc. has a 52-week low of $67.33 and a 52-week high of $100.93. The company has a market cap of $61.65 billion, a P/E ratio of 18.36, a P/E/G ratio of 0.91 and a beta of 0.77. The company has a quick ratio of 0.20, a current ratio of 0.20 and a debt-to-equity ratio of 0.52. The business has a 50-day simple moving average of $95.04 and a two-hundred day simple moving average of $83.91.

MetLife (NYSE:MET – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The financial services provider reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.13. MetLife had a net margin of 4.57% and a return on equity of 23.39%. The company had revenue of $13.52 billion for the quarter, compared to the consensus estimate of $19.67 billion. During the same quarter last year, the firm posted $2.02 earnings per share. The firm’s revenue was up 10.5% compared to the same quarter last year. Analysts predict that MetLife, Inc. will post 9.78 EPS for the current year. MetLife Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 4th were paid a dividend of $0.5925 per share. The ex-dividend date was Tuesday, August 4th. This represents a $2.37 dividend on an annualized basis and a dividend yield of 2.5%. MetLife’s payout ratio is 45.40%.

MetLife announced that its Board of Directors has initiated a share buyback program on Wednesday, August 5th that allows the company to repurchase $3.00 billion in shares. This repurchase authorization allows the financial services provider to buy up to 4.8% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its stock is undervalued.

Analysts Set New Price Targets Several brokerages have commented on MET. Mizuho increased their target price on MetLife from $95.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, July 9th. Atlantic Securities set a $103.00 price objective on MetLife in a research report on Wednesday, July 15th. Barclays boosted their target price on MetLife from $94.00 to $97.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. TD Cowen raised their price target on shares of MetLife from $87.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Finally, Jefferies Financial Group lifted their price target on shares of MetLife from $97.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, MetLife presently has a consensus rating of “Buy” and a consensus target price of $102.21.

View Our Latest Analysis on MET

About MetLife (Free Report)

MetLife, Inc (NYSE: MET) is a global financial services company that provides insurance, employee benefits and retirement solutions to individuals, employers and institutions. Its offerings include life insurance, dental and vision insurance, disability coverage, accident and health insurance, annuities, and retirement products.

Through its employer-focused business, MetLife helps organizations provide benefits and financial protection to their employees. The company also offers group insurance, individual protection products and investment management services through MetLife Investment Management, which serves institutional investors and retirement plans.

Founded in 1868, MetLife serves customers in the United States and operates internationally across Latin America, Asia, Europe and the Middle East.

See Also Five stocks we like better than MetLife Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer Sovereign AI: Palantir and Nebius Cut the Cloud Cord

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

The transaction involved 6,057 shares at $95.17 per share, representing a total value of ~$576,445. The shares traded were equal to 2% of the direct equity holdings held prior to the transaction.

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that Michel Khalaf, president and chief executive officer, and John McCallion, executive vice president and chief financial officer, and head of MetLife Investment Management, will participate in a fireside chat at the 2026 Keefe, Bruyette & Woods Annual Insurance Conference on Wednesday, Sept. 9, 2026, from 9:15 am to 9:55 am ET. The live webcast can be listened to by clicking here. Please visit the link at least 15 minut.

Emerald Investment Advisers LLC acquired a new position in MetLife, Inc. (NYSE:MET – Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 40,917 shares of the financial services provider’s stock, valued at approximately $3,462,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Westpac Banking Corp bought a new position in shares of MetLife during the second quarter valued at approximately $1,302,000. Sumitomo Life Insurance Co. bought a new stake in shares of MetLife in the 2nd quarter worth approximately $220,000. Landscape Capital Management L.L.C. bought a new stake in shares of MetLife in the 2nd quarter worth approximately $2,039,000. Korea Investment CORP purchased a new stake in shares of MetLife in the 2nd quarter worth approximately $19,580,000. Finally, EP Wealth Advisors LLC purchased a new stake in shares of MetLife in the 2nd quarter worth approximately $1,857,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

MetLife Trading Up 1.0% Shares of MET stock opened at $94.44 on Friday. The company has a current ratio of 0.20, a quick ratio of 0.20 and a debt-to-equity ratio of 0.52. MetLife, Inc. has a 12-month low of $67.33 and a 12-month high of $100.93. The stock has a market capitalization of $60.77 billion, a P/E ratio of 18.09, a P/E/G ratio of 0.73 and a beta of 0.78. The firm’s 50 day moving average is $92.41 and its 200 day moving average is $82.17.

MetLife (NYSE:MET – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The financial services provider reported $2.43 EPS for the quarter, beating the consensus estimate of $2.30 by $0.13. The firm had revenue of $13.52 billion during the quarter, compared to analyst estimates of $19.67 billion. MetLife had a net margin of 4.57% and a return on equity of 23.39%. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.02 EPS. Research analysts expect that MetLife, Inc. will post 9.72 earnings per share for the current year. MetLife Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 4th will be given a $0.5925 dividend. The ex-dividend date is Tuesday, August 4th. This represents a $2.37 annualized dividend and a yield of 2.5%. MetLife’s dividend payout ratio (DPR) is presently 45.40%.

MetLife announced that its Board of Directors has approved a share repurchase program on Wednesday, August 5th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the financial services provider to buy up to 4.8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.

Key Stories Impacting MetLife Here are the key news stories impacting MetLife this week:

Positive Sentiment: Wall Street Zen upgraded MetLife to a Buy rating, providing a favorable near-term sentiment catalyst for MetLife, Inc. (NYSE: MET). MetLife Upgraded by Wall Street Zen to Buy Rating Positive Sentiment: Dowling & Partners issued a positive outlook for MetLife’s earnings, reinforcing expectations for continued operating strength. This view follows the company’s latest reported quarter, when earnings per share exceeded consensus estimates and revenue increased year over year. DOWLING & PARTN Issues Positive Outlook for MetLife Earnings Neutral Sentiment: A review of life-insurance companies’ second-quarter results benchmarks MetLife (NYSE: MET) against its industry peers. The article may help investors assess relative performance, but the headline does not identify a new company-specific catalyst. Life Insurance Stocks Q2 Recap: Benchmarking MetLife Neutral Sentiment: Multiple articles cover Bruno Mars’ concerts, schedules, weather, ticket availability and fan experience at MetLife Stadium. Although potentially relevant to the stadium’s venue business, MetLife, Inc. is an insurance and financial-services company; the stadium’s naming rights do not make these events a material direct driver of MET shares. Bruno Mars Opens Four Nights at MetLife Tonight Analyst Ratings Changes Several equities analysts have recently weighed in on MET shares. Weiss Ratings upgraded MetLife from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, June 15th. Jefferies Financial Group increased their price objective on shares of MetLife from $97.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, July 10th. JPMorgan Chase & Co. raised their price objective on shares of MetLife from $106.00 to $108.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. UBS Group lifted their target price on shares of MetLife from $102.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Finally, Barclays upped their target price on shares of MetLife from $94.00 to $97.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $101.64.

View Our Latest Report on MetLife

About MetLife (Free Report)

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.

Featured Articles Five stocks we like better than MetLife 2 Biotech Stocks Shaping Up for Major Breakouts 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

BlackRock Inc. purchased a new position in shares of MetLife, Inc. (NYSE:MET – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 51,786,925 shares of the financial services provider’s stock, valued at approximately $4,381,692,000. BlackRock Inc. owned approximately 8.05% of MetLife as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Strs Ohio increased its position in MetLife by 16.6% during the fourth quarter. Strs Ohio now owns 326,091 shares of the financial services provider’s stock worth $25,742,000 after buying an additional 46,469 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH raised its position in MetLife by 2.1% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 714,193 shares of the financial services provider’s stock worth $56,712,000 after buying an additional 14,515 shares during the last quarter. PFA Pension Forsikringsaktieselskab acquired a new stake in MetLife in the fourth quarter valued at about $81,494,000. Evergreen Capital Management LLC lifted its holdings in shares of MetLife by 195.8% in the 4th quarter. Evergreen Capital Management LLC now owns 33,260 shares of the financial services provider’s stock valued at $2,626,000 after buying an additional 22,016 shares during the period. Finally, Principal Financial Group Inc. boosted its position in shares of MetLife by 2.2% during the 4th quarter. Principal Financial Group Inc. now owns 622,789 shares of the financial services provider’s stock worth $49,163,000 after purchasing an additional 13,657 shares in the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In Several research firms have weighed in on MET. Piper Sandler upped their target price on MetLife from $86.00 to $90.00 and gave the company a “neutral” rating in a report on Wednesday, June 24th. Weiss Ratings raised MetLife from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, June 15th. Atlantic Securities set a $103.00 target price on shares of MetLife in a report on Wednesday, July 15th. Barclays raised their price objective on MetLife from $94.00 to $97.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Finally, Morgan Stanley raised their target price on shares of MetLife from $93.00 to $103.00 and gave the company an “overweight” rating in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $101.07.

Get Our Latest Analysis on MetLife Key MetLife News Here are the key news stories impacting MetLife this week:

Positive Sentiment: DOWLING & PARTN raised its fiscal 2027 earnings estimate for MetLife to $10.85 per share from $10.75. The revision suggests improving analyst expectations for the insurer’s future profitability and is favorable for MET, although the new estimate remains above the broader current-year consensus of $9.70. MetLife FY2027 earnings estimate Neutral Sentiment: MetLife declared third-quarter 2026 dividends on several series of preferred stock, including Series A, Series D, Series E and Series F. The payments reinforce the company’s ongoing capital-return commitments, but they primarily affect preferred shareholders and are unlikely to materially change the valuation of MET common shares. MetLife preferred stock dividends Neutral Sentiment: MetLife published its 2025 sustainability report, highlighting research and insights related to its environmental, social and governance initiatives. The report may support the company’s long-term reputation with stakeholders, but it is not expected to have an immediate earnings impact. MetLife 2025 sustainability report Neutral Sentiment: Several headlines concern MetLife Stadium, including a new stadium CEO, rapid transitions between Jets and Giants games, and upcoming concerts. These stories relate to the sports and entertainment venue—not MetLife, Inc.’s insurance and financial-services operations—and should not materially affect MET stock. MetLife Stadium names new CEO MetLife Trading Up 0.2% NYSE MET opened at $96.83 on Wednesday. The company has a market capitalization of $62.31 billion, a price-to-earnings ratio of 18.55, a price-to-earnings-growth ratio of 0.75 and a beta of 0.78. MetLife, Inc. has a 12 month low of $67.33 and a 12 month high of $100.93. The company’s fifty day moving average price is $92.00 and its two-hundred day moving average price is $81.86. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.20 and a quick ratio of 0.20.

MetLife (NYSE:MET – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The financial services provider reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.13. The firm had revenue of $13.52 billion during the quarter, compared to analyst estimates of $19.67 billion. MetLife had a return on equity of 23.39% and a net margin of 4.57%.MetLife’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the company earned $2.02 earnings per share. As a group, research analysts predict that MetLife, Inc. will post 9.7 earnings per share for the current fiscal year.

MetLife declared that its board has approved a share buyback plan on Wednesday, August 5th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the financial services provider to buy up to 4.8% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

MetLife Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 4th will be given a dividend of $0.5925 per share. This represents a $2.37 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, August 4th. MetLife’s dividend payout ratio is presently 45.40%.

About MetLife (Free Report)

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.

Further Reading Five stocks we like better than MetLife The AI Boom Is Turning This Cable Maker Into a Stock to Watch A Star Investor Just Trimmed Amazon—Here’s What It means Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look Home Depot Analysts See a Path to $375 and Beyond

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

Posted by Defense World Staff on Aug 16th, 2026

Bridgewater Advisors Inc. bought a new position in MetLife, Inc. (NYSE:MET – Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 11,146 shares of the financial services provider’s stock, valued at approximately $1,073,000.

Other hedge funds have also recently made changes to their positions in the company. SWS Partners bought a new position in shares of MetLife in the second quarter worth $3,145,000. Oppenheimer Asset Management Inc. bought a new position in MetLife in the second quarter valued at $1,204,000. Northstar Group Inc. purchased a new position in shares of MetLife during the 2nd quarter valued at about $278,000. Butensky & Cohen Financial Security Inc. lifted its holdings in shares of MetLife by 0.6% in the 2nd quarter. Butensky & Cohen Financial Security Inc. now owns 69,202 shares of the financial services provider’s stock worth $5,855,000 after acquiring an additional 443 shares during the last quarter. Finally, Tema ETFs LLC raised its position in MetLife by 10.8% in the 2nd quarter. Tema ETFs LLC now owns 8,958 shares of the financial services provider’s stock worth $758,000 after purchasing an additional 870 shares during the period. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

MetLife Price Performance MET opened at $97.57 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.20 and a current ratio of 0.20. The stock has a market capitalization of $62.78 billion, a PE ratio of 18.69, a price-to-earnings-growth ratio of 0.75 and a beta of 0.78. The stock’s 50 day moving average price is $91.52 and its 200-day moving average price is $81.55. MetLife, Inc. has a 52-week low of $67.33 and a 52-week high of $100.93.

MetLife (NYSE:MET – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The financial services provider reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.13. The company had revenue of $13.52 billion during the quarter, compared to analyst estimates of $19.67 billion. MetLife had a return on equity of 23.39% and a net margin of 4.57%.The firm’s revenue was up 10.5% on a year-over-year basis. During the same quarter last year, the firm posted $2.02 earnings per share. On average, equities research analysts predict that MetLife, Inc. will post 9.7 EPS for the current year.

MetLife Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 4th will be given a $0.5925 dividend. This represents a $2.37 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, August 4th. MetLife’s dividend payout ratio (DPR) is currently 45.40%.

MetLife announced that its board has authorized a stock buyback plan on Wednesday, August 5th that permits the company to buyback $3.00 billion in outstanding shares. This buyback authorization permits the financial services provider to repurchase up to 4.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades MET has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their price objective on MetLife from $106.00 to $108.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Wall Street Zen downgraded MetLife from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. UBS Group increased their price objective on MetLife from $102.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Morgan Stanley upped their price target on shares of MetLife from $93.00 to $103.00 and gave the company an “overweight” rating in a report on Monday, July 6th. Finally, Mizuho increased their price target on shares of MetLife from $95.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, MetLife currently has an average rating of “Moderate Buy” and an average target price of $101.07.

Check Out Our Latest Stock Analysis on MET

MetLife Profile (Free Report)

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.

Featured Articles Five stocks we like better than MetLife Is Best Buy the AI Winner Hiding in the Electronics Aisle? Applied Materials Beat Everything but Wall Street’s Expectations for Margins Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MetLife, Inc. (NYSE:MET – Free Report).

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINE5,920 Shares in Salesforce Inc. $CRM Bought by Bridgewater Advisors Inc.

MetLife Pet Insurance today announced a partnership with America's VetDogs, a national nonprofit that provides service dogs to veterans, first responders and ac

MetLife, Inc. (MET) Q2 2026 Earnings Call Transcript

LOS ANGELES, Aug. 06, 2026 (GLOBE NEWSWIRE) -- The 2026 Pet Innovation Awards today announced that MetLife Pet Insurance is the recipient of the “Pet Insurance of the Year” award. The Pet Innovation Awards is an independent recognition platform highlighting the most innovative companies, services, and products in the highly competitive Pet care industry.

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced its second quarter 2026 results. Earnings Return Per Share on Equity (ROE)     2Q 2026 2Q 2026   Net Income $1.09 ROE 11.5%   Adjusted Adjusted Earnings $2.43 ROE 17.0% Net income increased 1%1 to $705 million, or $1.09 per share. Adjusted earnings increased 15% to $1.6 billion, driven by favorable underwriting and volume growth. Adjusted earnings per share increased 20% to $2.43. Premiums, fees and other revenues (PFOs) increa.

The MetLife Inc building is seen in Manhattan, New York, U.S., December 7, 2021. REUTERS/Andrew Kelly Purchase Licensing Rights, opens new tab

CompaniesAug 5 (Reuters) - Life insurer MetLife (MET.N), opens new tab posted a jump in second-quarter adjusted profit on Wednesday, powered by strong underwriting ​and broad volume growth, with standout results ‌in Asia and Latin America.

The industry has continued to benefit from resilient demand, robust sales growth and disciplined underwriting, while ​elevated interest rates have lifted investment returns.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

MetLife ​said premiums, fees and other revenue increased 7% ⁠in the second quarter to $13.7 billion.

This typically reflects ​the income insurers earn from selling insurance policies, annuities ​and related financial products.

Group benefits, which include employer-sponsored insurance products, posted a 25% increase in adjusted profit to $503 million.

Asia adjusted ​earnings grew 21% in the quarter, on a ​reported basis, while Latin America logged a 15% increase.

"This quarter further ‌reinforces ⁠our ability to create value for shareholders across cycles," CEO Michel Khalaf said in a statement.

The company's second-quarter net investment income surged 18% to $6.7 billion.

Insurers typically ​generate investment ​income by ⁠investing premiums they collect, primarily in bonds and other low-risk assets.

MetLife said adjusted ​earnings per share rose 20% to $2.43 in ​the ⁠three months ended June 30.

Founded in 1868, MetLife operates in more than 40 markets and is one of ⁠the ​world's largest life insurers, offering insurance, ​annuities, employee benefits and asset management services to individuals and institutions.

Reporting ​by Manya Saini in Bengaluru; Editing by Sriraj Kalluvila

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Legendary Jets' icon Bart Scott hosted the partnership unveiling with a "Back to Football" campaign event, debuting OUTFRONT as the exclusive IRL media partner to Jets advertisers

, /PRNewswire/ -- OUTFRONT Media (NYSE:OUT), one of the largest and most-trusted IRL media companies in the U.S., today announced a multi-year exclusive agreement with the New York Jets.

OUTFRONT and the New York Jets unveiled their exclusive, multi-year partnership during the "Back to Football" campaign event, featuring legendary Jets linebacker Bart Scott and introducing OUTFRONT as the exclusive IRL media partner for Jets advertisers.

.

Effective immediately, Jets advertiser partners can engage fans before, during and after game day through OUTFRONT's integrated offering of premium outdoor media, experiential activations and creator-led storytelling. Extending sponsorship beyond MetLife Stadium, the partnership connects brands with fans throughout the game-day journey—from transit hubs and commuter routes to the neighborhoods and destinations where fans gather before and after kickoff.

By connecting in-stadium sponsorships with OUTFRONT's digital network, brands can activate campaigns in near real time—responding to breaking sports moments, player milestones, rivalries and cultural conversations as they unfold. Participating brands also gain access to OUTFRONT Studios, the company's in-house creative team, which can adapt existing assets or develop original work purpose-built for IRL environments. Whether a sponsor is new to out-of-home or looking to optimize existing creative, OUTFRONT Studios can transform broadcast, digital and social campaigns into high-impact experiences for the street, the station and the stadium.

"New York Jets fans are among the most loyal in sports, and their passion doesn't begin at kickoff or end at the final whistle. This partnership helps brands connect with fans across the entire journey while unlocking faster, more dynamic ways to activate around culture in real time," said Stacy Minero, CMXO, OUTFRONT.

"Our fans are at the heart of everything we do, and our partnership with OUTFRONT creates new opportunities to connect with them in meaningful ways especially as we get back to football," said Jeff Fernandez, Jets SVP, Business Development + Ventures. "By combining our partners with OUTFRONT's expansive media platform, we're helping partners engage audiences throughout the region and creating experiences that extend the excitement of Jets football far beyond gamedays."

The partnership launches as sports marketers look to capitalize on a packed calendar of global sporting events. Following this summer's FIFA World Cup, during which OUTFRONT supported more than 115 brand campaigns across the tournament's 11 U.S. host cities, attention now turns to the upcoming college football and NFL seasons.

Legendary Jets' linebacker Bart Scott hosted a launch event during a Penn Station takeover to debut a "Back to Football," campaign featuring the partnership between OUTFRONT and the Jets.

"Together with the New York Jets, we're helping sponsors show up throughout the entire fan journey, extending their reach beyond the stadium walls and into the moments where culture, community, and fandom come to life. This is the future of sports marketing," remarked Chris Mallen, OUTFRONT's Vice President of Sports Marketing & Partnerships.

The launch also builds on the company's growing success with tapping into excitement around key cultural moments to co-create authentic IRL experiences. This includes previously-announced executive promotions and moves to increase its capabilities, a recent partnership with Formula E and a series of deals with host committees in key markets, including the Bay Area, Los Angeles, Atlanta, Dallas, and Miami.

About OUTFRONT Media

OUTFRONT is one of the largest and most trusted out-of-home media companies in the U.S., helping brands connect with audiences in the moments and environments that matter most. As OUTFRONT evolves, it's defining a new era of in-real-life (IRL) marketing, turning public spaces into platforms for creativity, connection, and cultural relevance. With a nationwide footprint across billboards, digital displays, transit systems, and other out-of-home formats, OUTFRONT turns creative into powerful real-world experiences. Its in-house agency, OUTFRONT STUDIOS, and award-winning innovation team, XLabs, deliver standout storytelling, supported by advanced technology and data tools that can drive measurable impact.

About the New York Jets

The New York Jets were founded in 1959 as the New York Titans and served as a charter member of the American Football League. Following the 1968 season, the team made history by becoming the first AFL franchise to win a world championship, defeating the Baltimore Colts in Super Bowl III—a victory widely credited with validating the AFL ahead of its 1970 merger with the NFL. Today, as one of the league's flagship franchises in the nation's largest media market, the Jets represent the sport on one of its biggest global stages.

The Jets enhance the fan experience through innovation and storytelling, including 1JD Entertainment, a digital content platform that connects fans across social and digital channels. The organization is also committed to community impact, supporting youth football, girls' and women's flag football, and programs serving disadvantaged communities throughout the tri-state area.

The Jets play at MetLife Stadium - one of the world's most successful multi use venues - and are headquartered at the Atlantic Health Jets Training Center in Florham Park, New Jersey.

Media Contacts:

Matt Biscuiti
The Lippin Group
[email protected]

OUTFRONT Media Press
[email protected] 

Stephan Bisson
OUTFRONT Media
[email protected]

Meghan Gilmore
New York Jets
[email protected] 

Website references and third-party hyperlinks included in this press release have been provided as a convenience, and the information contained on such websites and hyperlinks is not incorporated by reference into this press release.

SOURCE OUTFRONT Media Inc.

WHIPPANY, N.J.--(BUSINESS WIRE)--MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced the closing of approximately $1.2 billion in commitments to MetLife Investment Private Equity Partners Fund III (MIPEP III), the third fund in MIM's private equity investment platform for institutional investors. The new fund purchased a portfolio of approximately $754 million of private equity, venture capital and equity co-investment i.

Posted by Defense World Staff on Jul 31st, 2026

Arkadios Wealth Advisors boosted its holdings in MetLife, Inc. (NYSE:MET – Free Report) by 11.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 100,774 shares of the financial services provider’s stock after acquiring an additional 10,040 shares during the quarter. Arkadios Wealth Advisors’ holdings in MetLife were worth $7,127,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in MET. Empowered Funds LLC increased its holdings in shares of MetLife by 81.3% in the 1st quarter. Empowered Funds LLC now owns 93,574 shares of the financial services provider’s stock worth $6,618,000 after purchasing an additional 41,951 shares in the last quarter. Estate Counselors LLC bought a new position in shares of MetLife during the first quarter valued at $1,750,000. The Manufacturers Life Insurance Company boosted its position in shares of MetLife by 7.3% during the first quarter. The Manufacturers Life Insurance Company now owns 711,501 shares of the financial services provider’s stock valued at $50,317,000 after buying an additional 48,506 shares during the last quarter. Quantinno Capital Management LP boosted its position in shares of MetLife by 21.3% during the first quarter. Quantinno Capital Management LP now owns 621,375 shares of the financial services provider’s stock valued at $43,944,000 after buying an additional 109,004 shares during the last quarter. Finally, SummitTX Capital L.P. bought a new stake in MetLife in the 1st quarter worth about $1,855,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades MET has been the topic of several research analyst reports. Mizuho upped their target price on shares of MetLife from $95.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, July 9th. Piper Sandler lifted their price target on shares of MetLife from $86.00 to $90.00 and gave the stock a “neutral” rating in a research note on Wednesday, June 24th. Barclays boosted their price objective on shares of MetLife from $93.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. UBS Group increased their price objective on shares of MetLife from $102.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Finally, Keefe, Bruyette & Woods raised their target price on shares of MetLife from $98.00 to $105.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $100.50.

Check Out Our Latest Report on MET

MetLife Stock Performance MET opened at $97.17 on Friday. The company’s 50 day moving average is $88.43 and its 200 day moving average is $80.02. The company has a current ratio of 0.20, a quick ratio of 0.20 and a debt-to-equity ratio of 0.53. The company has a market cap of $62.52 billion, a price-to-earnings ratio of 18.83, a PEG ratio of 0.74 and a beta of 0.78. MetLife, Inc. has a 12-month low of $67.33 and a 12-month high of $97.80.

MetLife (NYSE:MET – Get Free Report) last announced its earnings results on Wednesday, May 6th. The financial services provider reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.15. MetLife had a net margin of 4.66% and a return on equity of 22.60%. The business had revenue of $14.18 billion during the quarter, compared to analysts’ expectations of $19.49 billion. During the same period in the prior year, the company earned $1.96 earnings per share. The firm’s revenue was up 2.7% on a year-over-year basis. On average, equities research analysts predict that MetLife, Inc. will post 9.89 EPS for the current year.

MetLife Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 4th will be paid a $0.5925 dividend. This represents a $2.37 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, August 4th. MetLife’s dividend payout ratio is 45.93%.

About MetLife (Free Report)

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.

Featured Stories Five stocks we like better than MetLife Microsoft Just Flipped the AI Spending Narrative Overnight Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling? Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of America Corp DE Raises Holdings in Xcel Energy Inc. $XEL

NEXT HEADLINE »Bank of America Corp DE Purchases 9,414,689 Shares of iShares 7-10 Year Treasury Bond ETF $IEF

TAMPA, Fla.--(BUSINESS WIRE)--MetLife Investment Management (“MIM”), the institutional asset management business of MetLife, Inc. (NYSE: MET), together with development partner ZOM Living, celebrated the grand opening of Emerald at MetWest with a ribbon-cutting ceremony attended by Tampa Mayor Jane Castor, project partners, and community leaders. The grand opening marks the completion of MetWest International, MIM's award-winning mixed-use development in Tampa's Westshore Business District that.

Posted by Defense World Staff on Jul 20th, 2026

California Public Employees Retirement System boosted its position in MetLife, Inc. (NYSE:MET – Free Report) by 2.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,063,550 shares of the financial services provider’s stock after purchasing an additional 24,552 shares during the quarter. California Public Employees Retirement System owned about 0.16% of MetLife worth $75,214,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Nordea Investment Management AB raised its holdings in shares of MetLife by 2.6% in the 4th quarter. Nordea Investment Management AB now owns 4,630,165 shares of the financial services provider’s stock valued at $366,524,000 after acquiring an additional 117,545 shares in the last quarter. Strs Ohio grew its holdings in shares of MetLife by 16.6% during the fourth quarter. Strs Ohio now owns 326,091 shares of the financial services provider’s stock worth $25,742,000 after purchasing an additional 46,469 shares in the last quarter. Evergreen Capital Management LLC grew its holdings in shares of MetLife by 195.8% during the fourth quarter. Evergreen Capital Management LLC now owns 33,260 shares of the financial services provider’s stock worth $2,626,000 after purchasing an additional 22,016 shares in the last quarter. PFA Pension Forsikringsaktieselskab bought a new position in shares of MetLife in the fourth quarter worth approximately $81,494,000. Finally, Diversified Trust Co. raised its stake in MetLife by 276.4% in the fourth quarter. Diversified Trust Co. now owns 31,246 shares of the financial services provider’s stock valued at $2,467,000 after purchasing an additional 22,945 shares in the last quarter. 94.99% of the stock is owned by institutional investors.

Trending Headlines about MetLife Here are the key news stories impacting MetLife this week:

Positive Sentiment: MetLife Stadium is hosting the World Cup final, which keeps the venue in the global spotlight and may highlight the company’s high-profile asset and brand visibility. FIFA insists MetLife Stadium’s pitch is ready for the World Cup final despite criticism Positive Sentiment: Heavy media coverage around ticket sales, fan guides, food and drink pricing, and kickoff details suggests strong interest and traffic around the event at MetLife Stadium. How to buy tickets to see Spain in World Cup Final at MetLife Neutral Sentiment: News about weather, heat, storms, air quality, and wildfire smoke could affect the event experience, but it does not directly change MetLife’s earnings outlook. World Cup final could be shaped by heat, storms and air quality at MetLife Stadium Neutral Sentiment: FIFA’s criticism of the pitch and the “money grab” controversy may create headline risk for the venue, but the impact on MetLife’s stock is likely limited unless the issue affects operations or reputation more broadly. NJ governor slams FIFA’s money grab over sales of MetLife World Cup pitch Negative Sentiment: Ongoing criticism about the field quality and pitch conditions at MetLife Stadium could dent the venue’s reputation, even though it is unlikely to materially affect MetLife’s insurance business. The MetLife trap: the controversial pitch threatening the final | OneFootball Wall Street Analysts Forecast Growth Several equities research analysts have issued reports on MET shares. JPMorgan Chase & Co. lifted their target price on shares of MetLife from $95.00 to $96.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Wall Street Zen lowered shares of MetLife from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Morgan Stanley raised their price objective on shares of MetLife from $93.00 to $103.00 and gave the company an “overweight” rating in a research report on Monday, July 6th. Mizuho upped their target price on shares of MetLife from $95.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, July 9th. Finally, Piper Sandler increased their target price on MetLife from $86.00 to $90.00 and gave the company a “neutral” rating in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $98.57.

Get Our Latest Report on MetLife

MetLife Stock Down 0.0% Shares of NYSE MET opened at $93.99 on Monday. The stock has a market capitalization of $60.48 billion, a P/E ratio of 18.21, a PEG ratio of 0.72 and a beta of 0.78. MetLife, Inc. has a one year low of $67.33 and a one year high of $94.86. The firm’s 50 day simple moving average is $85.80 and its two-hundred day simple moving average is $79.07. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.20 and a quick ratio of 0.20.

MetLife (NYSE:MET – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The financial services provider reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.15. MetLife had a net margin of 4.66% and a return on equity of 22.60%. The company had revenue of $14.18 billion during the quarter, compared to analysts’ expectations of $19.49 billion. During the same quarter in the prior year, the company earned $1.96 EPS. The firm’s revenue was up 2.7% on a year-over-year basis. As a group, analysts expect that MetLife, Inc. will post 9.94 EPS for the current fiscal year.

MetLife Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 4th will be paid a $0.5925 dividend. The ex-dividend date of this dividend is Tuesday, August 4th. This represents a $2.37 annualized dividend and a yield of 2.5%. MetLife’s payout ratio is currently 45.93%.

About MetLife (Free Report)

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.

See Also Five stocks we like better than MetLife Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MetLife, Inc. (NYSE:MET – Free Report).

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia Public Employees Retirement System Sells 137,675 Shares of Cloudflare, Inc. $NET

NEXT HEADLINE »California Public Employees Retirement System Sells 24,150 Shares of Cboe Global Markets, Inc. $CBOE

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. The earnings news release, financial supplement and related materials will be posted on MetLife's Investor Relations webpage at investor.metlife.com. MetLife will hold its second quarter 2026 earnings conference call on Thursday, August 6, 2026, from 9-10 a.m. (ET) via a live webcast. Please click on the following link to register: ht.